Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells.

An intense network of nerve fibers can be demonstrated in skeletal tissues, not only in the periosteum but also within cortical bone, growth plate, and bone marrow. This neuro-osteogenic network expresses a restricted number of signalling molecules, including neuropeptides, neurotransmitters, and neurotrophins. Several lines of evidence indicate that receptors for these molecules are present on bone cells and that activation of these receptors leads to changes in bone cell activities. In addition, deletion of signalling molecules has been shown to alter bone metabolism. In the present review, these studies are summarized with a focus on distribution and effects of vasoactive intestinal peptide.

Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors.

Vasoactive intestinal peptide has been suggested to play some roles in inflammatory dermatoses such as atopic dermatitis and psoriasis. The aim of this study is to clarify the precise mechanisms of how vasoactive intestinal peptide is implicated in the pathogenesis of these disorders. We investigated the expression of vasoactive intestinal peptide and its receptors in normal human fibroblasts and keratinocytes, as well as in a human epidermal keratinocyte cell line DJM-1, using reverse transcription polymerase chain reaction and northern blotting. Type I VIP receptor mRNA was expressed in normal human keratinocytes and DJM-1 cells, and the latter also expressed type II receptor in lesser amounts. Neither type I nor type II VIP receptor mRNA was detected in fibroblasts, and vasoactive intestinal peptide transcript was not found in any cells examined. Type I VIP receptor mRNA was upregulated by Th1 cytokines (interferon-gamma), Th2 cytokines (interleukin-4), and tumor necrosis factor alpha, as well as vasoactive intestinal peptide itself, suggesting the presence of an autoregulatory loop. Vasoactive intestinal peptide increased cAMP production and cell proliferation of DJM-1 cells, and also induced the production of inflammatory cytokines such as interleukin-6, interleukin-8, and RANTES. The production of cAMP and cytokines was abrogated by a type I VIP receptor selective antagonist, indicating that type I receptor mediates these effects. Overall, these results suggest that upregulation of vasoactive intestinal peptide receptors by cytokines from inflammatory cells in the dermis enhances the proliferation and cytokine production of keratinocytes in response to vasoactive intestinal peptide from nerve endings. This cytokine network around keratinocytes may be involved in the pathogenesis of inflammatory dermatoses.

A critical view of the methods for characterization of the VIP/PACAP receptor subclasses.

The binding properties of the three cloned VIP/PACAP receptors and their coupling to G proteins and effectors can be studied in cells expressing each recombinant protein. The data obtained in these models must be critically evaluated: the expression of a high receptor density may reveal irrelevant receptors states and coupling to non-cognate G protein, and entail a marked amplification of the response as well as distortions in the selectivity profile of full and partial agonists. These models are, however, of great interest in the design of selective agonists and antagonists for each receptor subtype. The availability of selective ligands will facilitate the identification of the receptor subtype responsible for PACAP and VIP actions in cells and tissues.

Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.

Regulation of Interleukin-6 (IL-6) production in bone marrow (BM)-derived stromal cells by neuropeptides, pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP), was examined. Both forms of PACAP, PACAP-27 and PACAP-38, as well as VIP significantly increased IL-6 production by rat BM-derived stromal cells at physiological concentrations ranging from 10(-10)-10(-8) M. The three related peptides (PACAP-27, -38, and VIP) stimulated the production of both cAMP and inositol 1,4,5-trisphosphate (IP3) in rat BM-derived stromal cells with similar 50% effective concentrations. The stimulatory potency of the three related peptides for the production of IL-6, cAMP, and IP3 was almost consistent, suggesting that the dual signaling transduction pathways may be involved in PACAP/VIP-induced IL-6 production in rat BM-derived stromal cells. The messenger RNA (mRNA) for the third subtype of PACAP receptor (PVR3) was found to be abundantly expressed in both BM-derived stromal cells and the BM tissue, whereas little of the mRNA for type 1 (PVR1) nor type 2 (PVR2) was detected. Furthermore, the mRNAs for PACAP and VIP were detected in the BM tissue, suggesting that both PACAP/VIP and PVR3 are synthesized in vivo in the BM. The results shown in this paper suggest that PACAP/VIP and their receptor play an important role in the IL-6 production and perhaps in the hematopoiesis in the BM.

Identification of vasoactive intestinal peptide receptor subtypes in the lacrimal gland and their signal-transducing components.

PURPOSE: To determine the presence of vasoactive intestinal peptide (VIP) receptor (VIPR) subtypes in the lacrimal gland and to determine if the components of the VIP signaling pathway for protein secretion also are present. METHODS: Immunofluorescence studies using conventional fluorescence microscopy or confocal microscopy were performed on fixed sections from rat lacrimal glands using antibodies raised against VIPRs types I and II, and four antibodies against five isoforms of adenylyl cyclase (AC) (II, III, IV, V/VI). Guanine nucleotide binding (G) proteins were detected by Western blotting. Changes in intracellular [Ca2+] ([Ca2+]i) were measured on fura-2-loaded acini in response to VIP. The effect of a myristoylated peptide corresponding to the pseudosubstrate sequence of protein kinase inhibitor (myr-PKI), the endogenous inhibitor of cyclic AMP (cAMP)-dependent protein kinase (PKA), was tested on VIP-stimulated peroxidase secretion. RESULTS: The VIPRs, types I and II, were found on the basolateral membranes of acinar and ductal cells and on myoepithelial cells. Western blotting showed the presence of alpha subunits of Gs, Gi3, G0 and G beta. The AC II was found exclusively on myoepithelial cells; AC IV was located intracellularly in all cells; AC III was found on ducts and possibly nerves; no AC V/VI was detected. The VIP (10(-8) M) caused a small but significant increase in [Ca2+]i of 26 +/- 9 nM. The VIP-stimulated protein secretion was inhibited 71% by myr-PKI. CONCLUSIONS: All components of the VIP signal transduction pathway in the lacrimal gland were present. These findings are consistent with a pathway where VIP released from parasympathetic nerves binds to VIPRs types I and II, activating G proteins, which in turn stimulate AC present on myoepithelial and acinar cells. The AC increases the intracellular cAMP concentration, which activates PKA to stimulate protein secretion. The VIP also stimulated Ca2+ influx, which could play a role in secretion.

[Directed mutagenesis of human recombinant receptors of vasoactive intestinal peptide of VIP1 and VIP2 type. Difference in structure-activity relationship]. / Mutagenèse dirigée des récepteurs recombinants humains du peptide intestinal vasoactif (VIP) de type VIP1 et VIP2. Différence de relation structure-activité.

OBJECTIVES: Two vasoactive intestinal peptide (VIP) receptor subtypes have been cloned. We studied the structure-function relationship of human VIP1 and VIP2 receptors by mutating residues specifically conserved in extracellular domains of these receptors: N-terminal domain (E36, I43, S64, D132 and F138 in VIP1 receptor corresponding to E24, I31, S53, D116 and F122 in VIP2 receptor) and second loop (T288 and S292 in VIP1 receptor corresponding to T274 and S278 in VIP2 receptor). METHODS: Residues were mutated into alanine (A) and the corresponding cDNAs were transfected into Cos cells. Wild-type and mutated receptors were characterized in transfected cells by ligand binding assay using 125I-VIP and cAMP measurements upon VIP challenge. RESULTS: Regarding the VIP1 receptor, no specific binding of 125I-VIP could be detected on Cos cells transfected with the E36A mutant whereas other mutants, with the exception of S64A, exhibited dissociation constants similar to that of the wild-type receptor. The S64A mutant showed a 3-fold increase of its dissociation constant as compared to the wild-type receptor. cAMP experiments showed that the E36A mutant mediated a very weak stimulation by VIP. Regarding the VIP2 receptor, no specific binding of 125I-VIP could be detected on Cos cells transfected with the E24A. I31A and T274A mutants whereas all other mutants exhibited dissociation constants similar to that of the wild-type receptor. cAMP experiments showed that the E24A mutant mediated a very weak stimulation by VIP. Regarding I31A and T274A mutants, the EC50 values were increased 10 and 50 times as compared to the wild-type receptor, respectively. CONCLUSION: a) The conserved glutamate (E) residue in the N-terminal domain of VIP1 and VIP2 receptors is crucial for VIP binding; b) The VIP2 receptor contains two conserved residues isoleucine 31 and threonine 274 which are critical for VIP binding while they can be mutated without loss of function in the VIP1 receptor. This difference in the structure-function relationship should be instrumental for the development of a selective pharmacology of VIP receptor subtypes.

Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes are differently expressed in rat transplanted pituitary tumours (SMtTW) and in the normal gland.

The expression of the pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide (PACAP/VIP) receptor subtypes was evaluated in the normal rat pituitary gland and in different rat spontaneous transplantable SMtTW tumours (SMtTW2 which expresses prolactin (PRL), SMtTW10 which expresses GH and SMtTW3 which expresses both PRL and GH) by measurement of PACAP/VIP-stimulated adenylate cyclase activity and detection of the presence of mRNA coding for the different receptor forms. In normal glands, the order of potency of the peptides suggested that adenylate cyclase activity was mediated through interaction with PACAP selective receptors (PACAP I receptors); mRNAs coding for the PACAP I receptor, but also for the PACAP II VIP2 receptor, were detected. In SMtTW2 tumours, the functional response was close to that observed in the presence of PACAP II VIP2 receptors; mRNAs coding for PACAP I and PACAP II VIP1 and PACAP II VIP2 receptors were detected. In the SMtTW10 tumours, the functional response was complex but compatible with the involvement of PACAP I and PACAP II receptors; mRNAs coding for the PACAP I and PACAP II VIP1 receptors were detected. In the SMtTW3 tumour, the profile was similar to that of the normal pituitary gland and the mRNA coding for the PACAP I receptor only was detected. Thus, while the control of normal pituitary gland adenylate cyclase activity by PACAP and VIP was mediated by PACAP-selective receptors, in spontaneous transplantable tumours a variable profile was observed and PACAP, as well as VIP1 and VIP2 receptors, may contribute to the responses.

Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines.

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) are structurally-related neuropeptides that function as trophic factors in addition to their more classical roles as neurotransmitters. Binding and molecular cloning studies have shown that their actions are mediated by receptors encoded by at least three different genes. VIP binding has been demonstrated on many tumor types, and radiolabeled VIP has recently been used as a novel method to localize intestinal tumors in humans and their sites of metastasis. To determine the receptor subtype and level of gene expression, we screened breast, intestinal, and pancreatic, cell lines by Northern blot analysis. Breast lines expressed VIP/PACAP1 receptor mRNA levels comparable to intestinal lines, in agreement with the studies showing particularly high VIP binding in these tumors and their derived cell lines. Pancreatic cell lines expressed mRNA for several receptor types. This extends the potential utility of VIP and PACAP in the localization of tumors, and because VIP and PACAP may regulate the growth rate of some tumors by autocrine or other mechanisms, the identification of receptor subtypes on these lines sets the stage for studies in which the activity of these individual receptors in growth and other processes can be investigated.

Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.

Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) are hypothalamic factors believed to play a role in the regulation of anterior pituitary cell function. However, little is known about the expression of PACAP/VIP receptor (PVR) subtypes in such cells. Three PVR subtypes have recently been cloned: the PACAP-selective PVR1, and PVR2 and PVR3, which exhibit similar affinities for PACAP and VIP. In the present study we used the reverse transcription-polymerase chain reaction with PVR-specific primers to identify the PVR messenger RNAs (mRNAs) expressed in the somatotroph-like GH4C1 and the gonadotroph-like alpha T3-1 cell lines. In parallel, the effects of PACAP and VIP on intracellular signaling were studied. GH4C1 cells were found to express mRNA only for the PVR3, and neither PVR1 nor PVR2 mRNA was found. PACAP and VIP stimulated Ca2+ influx responses in individual GH4C1 cells and were equipotent in stimulating cAMP production (EC50, 15 nM) in GH4C1 cell populations, but failed to stimulate inositol phospholipid (PI) turnover, results consistent with the expression of a PVR3. In contrast, alpha T3-1 cells expressed mRNA for PVR1 and PVR3, but not PVR2. The predominant splice variant forms of PVR1 observed were PVR1s and PVR1hop, although the other forms (PVR1hiphop and PVR1hip) were also seen at much lower levels. PACAP stimulated a Ca2+ store-dependent Ca2+ spike and a sustained Ca2+ influx in individual alpha T3-1 cells, whereas VIP only stimulated Ca2+ influx. PACAP (EC50, 3 nM) was approximately 1000-fold more potent than VIP (EC50, approximately 3 microM) in stimulating cAMP production. PACAP also stimulated PI turnover (EC50, approximately 20 nM), whereas VIP stimulated PI turnover only at very high (10 microM) concentrations. These results are indicative of the expression of a PVR1. Rat anterior pituitary tissue expressed mRNAs for PVR1, PVR3, and low levels of PVR2. The coexpression of different PVRs in the same cell type and the differential expression of PVRs in different cell types would allow for a complex regulation of anterior pituitary gland function by PACAP and VIP.

Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung.

Peptidergic nerves in the respiratory tract release vasoactive intestinal peptide (VIP) and substance P (SP), which mediate physiological and immune functions. Antipeptide antibodies to type I VIP receptor (VIPR) and NK-1-type SP receptor (SPR) were used to identify these receptors in normal rat lungs. VIPRs and SPRs were detected on airway epithelium from the trachea to the respiratory bronchioles but not in alveoli, submucosal glands, or pulmonary smooth muscle, except for that of some pulmonary veins. VIPRs also were expressed on macrophages around capillaries, in tracheal and bronchial connective tissue, in alveolar walls, and in the subintima of pulmonary veins and some arterioles. The absence of receptors from airway smooth muscle and submucosal glands implies that mediation of some known effects of SP and VIP may be epithelial or macrophage dependent. Other types of VIPRs and SPRs on airway glands and smooth muscle may transduce direct effects. The similar localization of VIPRs and SPRs in rat lung suggests that VIP and SP may coordinately regulate some pulmonary functions.

Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene.

Vasoactive intestinal peptide (VIP) and other members of the pituitary adenylyl cyclase-activating peptide (PACAP) and secretin neuroendocrine peptide family are recognized with specificity by related G protein-coupled receptors. We report here the cloning, characterization, and chromosomal location of the gene encoding the human type I VIP receptor (HVR1), also termed the type II PACAP receptor. The gene spans approximately 22 kb and is composed of 13 exons ranging from 42 to 1400 bp and 12 introns ranging from 0.3 to 6.1 kb. Primer extension analysis with poly(A)+ RNA from human HT29 colonic adenocarcinoma cells indicated that the transcription initiation site is located at position -110 upstream of the first nucleotide (+1) of the translation start codon, and 75 nt downstream of a consensus CCAAT-box motif. The G+C-rich 5' flanking region contains potential binding sites for several nuclear factors, including Sp1, AP2, ATF, interferon regulatory factor 1, NF-IL6, acute-phase response factor, and NF-kappa B. The HVR1 gene is expressed selectively in human tissues with a relative prevalence of lung > prostate > peripheral blood leukocytes, liver, brain, small intestine > colon, heart, spleen > placenta, kidney, thymus, testis. Fluorescence in situ hybridization localized the HVR1 gene to the short arm of human chromosome 3 (3p22), in a region associated with small-cell lung cancer.

Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions.

Vasoactive intestinal polypeptide (VIP) has a variety of physiological effects. Pharmacological evidence suggesting that VIP acts via multiple receptors has been confirmed by the cloning of two VIP receptors (VIP1 and VIP2) with very different amino acid sequences. At both the VIP1 and the VIP2 receptor VIP, PHI, PACAP38, and PACAP27 have similar potency to each other. Only the VIP1 receptor is activated by secretin. The messenger RNAs (mRNAs) for the two receptors have completely different distributions as mapped by in situ hybridization histochemistry. VIP1 receptor mRNA is predominantly found in the lung, small intestine, thymus, and within the brain in the cerebral cortex and hippocampus. VIP2 receptor mRNA is present in a number of areas where VIP acts but VIP1 receptor mRNA is not present, including the stomach and testes. In the CNS VIP2 receptor mRNA is exclusively present in areas associated with neuroendocrine function, including several hypothalamic nuclei. In the periphery, it is also present in the pituitary and in pancreatic islets.

VIP suppression in the intestine and cerebral cortex following administration of VIP antiserum to newborn rats.

The administration of vasoactive intestinal peptide (VIP) antiserum to newborn rats significantly reduced the VIP content, both in the cerebral cortex and in intestinal epithelial cells. The decrease was observed at postnatal days 14 and 21 and also in 90 day-old animals. The neonatal treatment produced a significant increase in the density of high- and low-affinity binding sites for VIP in the cerebral cortex at post-natal days 14 and 21 whereas in the intestinal epithelial cells only the low-affinity binding sites were up-regulated at the same time points. VIP suppression induced by neonatal administration of the corresponding antiserum may represent a useful approach to further characterize the physiological role of this neuropeptide.

Structure-activity relationships for relaxation of smooth muscle by VIP.

Utilizing VIP and five VIP analogues, concentration-response curves for relaxation of rat mesenteric artery and rat gastric longitudinal muscle were determined for comparison with our previously published radioligand binding data on rat smooth muscle and other tissues. The biological potency of the VIP analogues in the present study compared more closely with their potency for VIP receptor binding in smooth muscle tissue (arteries) vs. other tissues (pituitary, brain, liver).